Prostate Cancer - Results from #40

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches. March 10, 2025

The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer. March 10, 2025

Assessing operative variability in robot-assisted radical prostatectomy (RARP) through AI. March 7, 2025

Association of marginalization and PSMA-PET in prostate cancer: An analysis of the Ontario PSMA-PET Registry for Recurrent Prostate Cancer. March 7, 2025

Quality of Life Two Years After Diagnosis of Low-Risk Prostate Cancer in the Treatment Options for Prostate Cancer Study Cohort. March 7, 2025

Using real-world, population-level data to assess the uptake of active surveillance for low-grade prostate cancer before and after the release of clinical guidelines. March 7, 2025

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. March 7, 2025

Confirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management. March 6, 2025

Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose-Rate Brachytherapy for Prostate Cancer. March 6, 2025

Multi-gene risk-score for prediction of clinical outcomes in treatment-naïve metastatic castrate resistant prostate cancer. March 6, 2025

Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. March 6, 2025

Intact Glycopeptide Analysis of Human Prostate Tissue Reveals Site-Specific Heterogeneity of Protein Glycosylation in Prostate Cancer. March 6, 2025

5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies. March 6, 2025

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences. March 5, 2025

Cancer mortality predictions for 2025 in Latin America with focus on prostate cancer. March 5, 2025

Perceptions and Use of Germline Genetic Testing Among Patients With Prostate Cancer. March 5, 2025

Does Size Matter? A Retrospective Study Analysing the Size of PI-RADS 4 Lesions and Its Associated Prostate Cancer Positivity with Transperineal Prostate Biopsy. March 5, 2025

A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer. March 5, 2025

Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume. March 5, 2025

Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. March 5, 2025

Page 3 of 1465